Pharmafile Logo

Veeda Clinical Research Pvt Ltd

We are one of the largest Independent CROs in India with a scientific edge, technical skills and better foresight for BA BE Studies & Clinical trials; with an objective of becoming a catalyst for enhanced drug developments to facilitate better patient treatments.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Havas Life London

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…

View Profile

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.

View Profile

Uniphar

Uniphar Group is a trusted global partner to pharmaceutical, medtech, and supply chain and retail companies, working to improve patient access to medicines around the world.

View Profile

Company Details

"Vedant Complex", Nr. YMCA club, S. G. Highway, Ahmedabad- 380015, Gujarat, India, "Vedant Complex", Nr. YMCA club, S. G. Highway, Ahmedabad- 380015, Gujarat, India, VEEDA CLINICAL RESEARCH® PVT. LTD., Ahmedabad, India, 380015, India
+91 79677 73000

 Latest Content from PMHub 

Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries

Press Releases | August 21, 2025 | Uniphar

Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...

What oncologists really want from booth strategy

Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company  At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30...

How smart spaces and real-time strategy transformed ASCO® 2025

Nick Bellomo, Director of Technology and Engagement, Inizio Medical ASCO® 2025 wasn’t just about oncology breakthroughs - it was also a showcase for how technology is redefining congress engagement. Supporting...

The science is shifting in oncology: Are you ready to evolve with it?

Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke. This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic...

Reimagine health with Inizio.

Videos and Podcasts | August 19, 2025 | Inizio

At Inizio, we provide tailored, innovative solutions to help health and life sciences companies with their clinical development and commercialization journeys, maximizing patient access. Our experts guide you through each...

Navigating NHS Market Access: Policy Change and Opportunity in England

With the changes at NHS England and the publishing of the 10-Year Plan, there is a lot of talk of change in the NHS in England. But what do these...

Cuttsy+Cuttsy welcomes new team members

Press Releases | August 13, 2025 | Cuttsy + Cuttsy

Cuttsy+Cuttsy is excited to announce the addition of three talented professionals to the team: Flo, an enthusiastic Account Executive; Vicki, a creative Graphic Designer; and Jo, a detail-driven Artworker

Unlocking the future of Learning

By Potter Li and Aaron Fletcher

Medical Misinformation and Sensationalism in the Age of Social Media

In today’s digital age, misinformation spreads faster than ever, often driven by sensational headlines and influencer content. These sources of misinformation often overshadow evidence-based content, creating confusion for both healthcare...

Patient Recruitment in Oncology: A Phase III Melanoma Case Study

Boosting screening & enrollment rates in a global oncology trial